面部评估电池可以区分阿尔茨海默氏症和前性痴呆症患者吗?
Fabrissio Grandi1,2, Loreto Olavarría1,3,4, Mario A Parra5
1Geroscience Center for Brain Health and Metabolism (GERO), Faculty of Medicine, University of Chile, Santiago, Metropolitan Region, 7750162, Chile.
概括
智利前额评估电池 (FAB-Ch) 有效地识别痴呆症,但无法区分阿尔茨海默病痴呆症 (ADD) 和行为变异前性痴呆症 (bvFTD). 它揭示了痴呆症患者的执行功能障碍.
科学领域:
- 神经科学
- 认知心理学
- 临床神经学
背景情况:
- 执行功能评估对于分辨神经退行性疾病至关重要.
- 面部评估电池 (FAB) 是一种常见的工具,但其在区分阿尔茨海默病痴呆症 (ADD) 和行为变异前性痴呆症 (bvFTD) 中的有用性仍在争论中.
- 智利版本的FAB (FAB-Ch) 需要对其在这些条件下的诊断准确性进行评估.
研究的目的:
- 评估FAB-Ch在区分ADD和bvFTD中的诊断实用性.
- 通过集群分析探索痴呆症中的执行功能.
主要方法:
- 对288名参与者进行了评估,其中包括45名ADD患者,33名bvFTD患者和208名认知不受损的对照患者.
- 使用接收器操作特征 (ROC) 曲线来确定FAB-Ch的区分能力.
- 在痴呆症患者中,分层集群分析发现了不同的执行特征.
主要成果:
- 与对照组相比,痴呆症患者的FAB- Ch得分显著较低 (p < .001).
- 在ADD和bvFTD组之间没有发现FAB- Ch得分的显著差异 (p = .59).
- 在FAB-Ch中,痴呆症与对照群的差异很大 (AUC=0. 882),但ADD与bvFTD的差异很小 (AUC=0. 465).
- 在痴呆症组中,分组分析发现了三种不同的执行特征.
结论:
- 在区分痴呆症和认知正常状态方面,
- FAB-Ch没有区分ADD和bvFTD.
- FAB-Ch对执行功能障碍敏感,有助于鉴定痴呆症的严重程度和异质性.
相关概念视频
01:30Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:21Association Areas of the Cortex
6.2K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
6.2K
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260